In Vivo Anti-Inflammatory, Anti-Bacterial and Anti-Diarrhoeal Activity of Ziziphus Jujuba Fruit Extract

BACKGROUND: Ziziphus jujuba belongs to family Rhamnaceae widely distributed in subtropical and tropical countries. It is used traditionally for several pharmacological purposes including anti-inflammation, antidiarrhoeal and antibacterial, as well as tonic and sometimes as hypnotic (sedative).AIM: To determine the in vivo antidiarrhoeal, antibacterial and anti-inflammatory activities of Z. jujuba fruit ethanolic extract.METHOD: The fruit was macerated and extracted by 95% (v/v) ethanol. The antidiarrhoeal activity was evaluated using castor oil and Escherichia coli induced diarrhoea mouse model. The antidiarrhoeal and antibacterial activity was investigated at graded doses (400-1200 mg/kg). The anti-inflammatory effects were tested using the carrageenan-induced paw oedema in female Wistar rats. Rat’s treatment groups received tragacanth, 100 mg/kg diclofenac sodium, 800 mg/kg, 1200 mg/kg or 1600 mg/kg of an ethanolic extract of Z. jujuba (EEZJ). All treatment groups were fed with the compounds one hour before carrageenan injection at of rat’s paw. Also, the EEZJ was further analysed by HPLC-PDA system for identification of the presence of betulinic acid and quercetin.RESULTS: EEZJ different doses did not show inhibitory activity against castor oil induced diarrhoea except for the higher (1200 mg/kg) dose. However, the frequency of defecation of stools and watery stool were reduced significantly when compared to control group (P ≤ 0.05 and P ≤ 0.01 respectively), resulted in overall 67% inhibition of diarrhoea. Our anti-inflammatory results demonstrated that EEZJ was able to inhibit the carrageenan-induced paw oedema in rats to a significant degree (p ≤ 0.05) and the paw volume and thickness of both left and right paw were affected compared to the negative control group.CONCLUSION: EEZJ possesses antidiarrhoeal and antibacterial activity in a dose depending manner and may provide a pharmacological basis for its clinical use in diarrheal diseases. The activity may partially be due to the presence of betulinic acid and quercetin

Effects of Hibiscus sabdariffa on high blood pressure, lipid profile and C- reactive protein among adult hypertensive patients

BackgroundHypertension is a leading cause of mortality and morbidity worldwide. Hibiscus is a cheap readily available preparation.AimsWe aimed to assess the effect of Hibiscus sabdariffa on blood pressure, lipid profile, plasma sugar, and h-sensitive C-reactive protein.MethodsThis is a prospective cohort study conducted among 19 College staff members at the University of Tabuk, Saudi Arabia during January 2020. The participants signed written informed consent, then responded to a questionnaire to report their demographic data. At baseline,  the blood pressure was measured, anthropometric measures collected, and, and a blood sample was taken to measure fasting plasma sugar, serum cholesterol, triglycerides, high-density lipoproteins, and high-sensitive C-reactive protein. Participants thereafter took Hibiscus sabdariffa for four weeks, then the above measurements were repeated. The compliance of the participants was also assessed.Results No significant effects of Hibiscus sabdariffa consumption were observed on systolic and diastolic blood pressure, fasting plasma glucose, lipid profile, and high-sensitive C-reactive protein, P-value< 0.05.ConclusionNo significant effects were observed among Hibiscus sabdariffa users on blood pressure, plasma sugar, lipid profile, and C-reactive protein. Further larger multicenter studies are recommended

Dapagliflozin effects on hospitalization for heart failure reduction, and major adverse cardiovascular events

BackgroundUntil recently, there are no available preventive measures for macrovascular complications of diabetes mellitus (DM). Sodium-glucose co-transporter inhibitors (SGLT-2i) are a relatively new class of medications with cardio-renal protection. However, it is unknown, whether this is a class effect. Also, the exact mechanisms of action are not fully understood.AimsThe current review aimed to assess dapagliflozin effects on the major cardiovascular adverse events (MACE) and heart failure hospitalization rate (HHF) and its mechanisms of action.Methods The Pub Med, MEDLINE, and Google Scholar databases were systematically searched for relevant articles. Articles published in the English language from the first available article up to November 2019 were approached. The terms dapagliflozin, SGLT-2i, MACE, HHF, and mechanisms of action were used with proteans AND or OR. Out of two hundred-ten articles retrieved, only twenty-nine fulfilled the inclusion and exclusion criteria.Results Dapagliflozin reduced HHF, all-cause mortality, bumetanide induced hyperuricemia, and interstitial fluid volume with a lower rate of diuretic use. Possible mechanisms of action were: a reduction of oxidative stress, lowering of cardiac hexosamine biosynthetic pathway activation, reduced cytosolic sodium and calcium, and increased serum magnesium. Dapagliflozin effects on MACE are mixed. The above effects seem to be a class character across various population including normal people without diabetes with no differences across gender.ConclusionDapagliflozin reduced HHF (superior to empagliflozin) and all-cause mortality. The drug acts at cellular levels and not simple diuresis and haemoconcentration